In today’s session Sarepta Therapeutics Inc (SRPT) recorded an unusually high (2,070) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious SRPT decrease. With 2,070 contracts traded and 238044 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: SRPT170120P00050000 closed last at: $6.3 or 10.5% up. About 487,976 shares traded hands. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 222.82% since March 15, 2016 and is uptrending. It has outperformed by 217.34% the S&P500.
Analysts await Sarepta Therapeutics Inc (NASDAQ:SRPT) to report earnings on November, 3. They expect $-1.31 earnings per share, down 4.80% or $0.06 from last year’s $-1.25 per share. After $-1.34 actual earnings per share reported by Sarepta Therapeutics Inc for the previous quarter, Wall Street now forecasts -2.24% EPS growth.
Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage
Out of 19 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 11 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 58% are positive. $108 is the highest target while $4 is the lowest. The $53.06 average target is 5.93% above today’s ($50.09) stock price. Sarepta Therapeutics has been the topic of 49 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Buy” rating given on Thursday, August 27 by Robert W. Baird. SunTrust downgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) rating on Friday, August 7. SunTrust has “” rating and $33 price target. The rating was initiated by Janney Capital with “Neutral” on Wednesday, April 20. The stock has “Hold” rating given by Jefferies on Tuesday, April 26. The firm has “Outperform” rating given on Friday, October 2 by Wedbush. On Tuesday, June 7 the stock rating was upgraded by Wedbush to “Outperform”. Roth Capital maintained Sarepta Therapeutics Inc (NASDAQ:SRPT) on Thursday, September 3 with “Buy” rating. The rating was maintained by Needham on Friday, October 2 with “Buy”. The firm has “Buy” rating by Bank of America given on Friday, October 23. RBC Capital Markets upgraded it to “Outperform” rating and $83 target price in Monday, September 19 report.
Insitutional Activity: The institutional sentiment increased to 1.16 in Q2 2016. Its up 0.32, from 0.84 in 2016Q1. The ratio increased, as 31 funds sold all Sarepta Therapeutics Inc shares owned while 32 reduced positions. 31 funds bought stakes while 42 increased positions. They now own 33.70 million shares or 3.23% less from 34.83 million shares in 2016Q1.
Millennium Ltd Com has 0.01% invested in the company for 343,450 shares. Financial Architects has invested 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Gilder Gagnon Howe & Com Limited Liability Corp last reported 17,990 shares in the company. Emerald Mutual Fund Advisers has 0.26% invested in the company for 247,086 shares. Morgan Stanley has 0.01% invested in the company for 967,727 shares. Goldman Sachs Grp last reported 441,776 shares in the company. Proshare Advsrs Limited Liability, a Maryland-based fund reported 39,296 shares. Perceptive Advsr Ltd has 4.98% invested in the company for 3.77M shares. Blackrock holds 0% or 18,196 shares in its portfolio. Metropolitan Life Insurance Com Ny holds 0% or 31,776 shares in its portfolio. Amici Limited Liability Company reported 25,000 shares or 0.09% of all its holdings. Vanguard Grp accumulated 3.11 million shares or 0% of the stock. Raymond James & Associate has invested 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Stifel Financial Corp holds 0% or 23,076 shares in its portfolio. Nationwide Fund Advisors holds 0% or 28,047 shares in its portfolio.
Insider Transactions: Since September 14, 2016, the stock had 0 insider buys, and 7 insider sales for $7.44 million net activity. Ruff Shamim sold $438,660 worth of stock or 7,311 shares. The insider Howton David T sold $465,200. Kaye Edward M. MD had sold 24,352 shares worth $1.22 million. On Monday, September 19 Aphale Jayant sold $1.75 million worth of the stock or 35,000 shares.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $2.48 billion. The Firm is focused on the discovery and development of ribonucleic acid -targeted therapeutics for the treatment of rare, infectious and other diseases. It currently has negative earnings. The Firm operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
SRPT Company Profile
Sarepta Therapeutics, Inc., incorporated on June 5, 2013, is a biopharmaceutical company. The Firm is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Firm is engaged in the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Firm is primarily focused on advancing the development of its disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. The Firm is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.
More notable recent Sarepta Therapeutics Inc (NASDAQ:SRPT) news were published by: Benzinga.com which released: “Exclusive: SunTrust Managing Director Goes Over Sarepta Therapeutics’ Story” on October 17, 2016, also Fool.com with their article: “Here’s Why Sarepta Therapeutics, Inc’s Stock is Jumping Again” published on September 20, 2016, Fool.com published: “Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.” on October 10, 2016. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) were released by: Fool.com and their article: “Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc” published on September 28, 2016 as well as Businesswire.com‘s news article titled: “Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research …” with publication date: September 29, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.